Literature DB >> 24694473

Prognostic value of myocardial damage markers in patients with chronic heart failure with atrial fibrillation.

Yoichiro Otaki1, Takanori Arimoto, Hiroki Takahashi, Shinpei Kadowaki, Daisuke Ishigaki, Taro Narumi, Yuki Honda, Tadateru Iwayama, Satoshi Nishiyama, Tetsuro Shishido, Takehiko Miyashita, Takuya Miyamoto, Tetsu Watanabe, Isao Kubota.   

Abstract

OBJECTIVE: The aim of the present study was to examine the relationship between myocardial damage caused by atrial fibrillation (AF) and subsequent cardiovascular events in AF patients with chronic heart failure (CHF). METHODS AND
RESULTS: We measured the serum levels of heart-type fatty acid binding protein (H-FABP) and high-sensitivity troponin T in 402 consecutive CHF patients with chronic AF (CHF-AF, n=201) or sinus rhythm (CHF-SR, n=201). The patients with CHF-AF had higher H-FABP and troponin T levels than those with CHF-SR. In order to examine the prognostic value of myocardial damage markers in CHF-AF and CHF-SR patients, we followed the above patients and analyzed their clinical outcomes. A multivariate Cox proportional hazard analysis revealed that both the serum H-FABP and troponin T levels independently predicted subsequent cardiovascular events. A Kaplan-Meier analysis demonstrated that the rate of cardiovascular events was higher in the patients with elevated H-FABP and troponin T levels. The optimal cut-off values for the myocardial damage markers of cardiovascular events were higher in the CHF-AF patients than in the CHF-SR patients (H-FABP, 5.4 vs. 4.6 ng/mL and troponin T, 0.030 vs. 0.013 ng/mL).
CONCLUSION: Myocardial damage advances in association with the presence of AF and is associated with subsequent cardiovascular events in both CHF-AF and CHF-SR patients. In this study, the cut-off values for the myocardial damage markers were higher in the CHF-AF patients than in the CHF-SR patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 24694473     DOI: 10.2169/internalmedicine.53.1293

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  7 in total

Review 1.  Cardiovascular Biomarkers: Lessons of the Past and Prospects for the Future.

Authors:  Farah Omran; Ioannis Kyrou; Faizel Osman; Ven Gee Lim; Harpal Singh Randeva; Kamaljit Chatha
Journal:  Int J Mol Sci       Date:  2022-05-19       Impact factor: 6.208

2.  Heart-type fatty acid-binding protein: an overlooked cardiac biomarker.

Authors:  Harsh Goel; Joshua Melot; Matthew D Krinock; Ashish Kumar; Sunil K Nadar; Gregory Y H Lip
Journal:  Ann Med       Date:  2020-08-04       Impact factor: 4.709

3.  Clinical Significance of Arterial Velocity Pulse Index in Patients With Stage B Heart Failure With Preserved Ejection Fraction.

Authors:  Takashi Hitsumoto
Journal:  Cardiol Res       Date:  2019-06-07

4.  Skin Autofluorescence as a Predictor of First Heart Failure Hospitalization in Patients With Heart Failure With Preserved Ejection Fraction.

Authors:  Takashi Hitsumoto
Journal:  Cardiol Res       Date:  2020-06-03

Review 5.  Heart-Type Fatty Acid-Binding Protein (H-FABP) and its Role as a Biomarker in Heart Failure: What Do We Know So Far?

Authors:  Richard Rezar; Peter Jirak; Martha Gschwandtner; Rupert Derler; Thomas K Felder; Michael Haslinger; Kristen Kopp; Clemens Seelmaier; Christina Granitz; Uta C Hoppe; Michael Lichtenauer
Journal:  J Clin Med       Date:  2020-01-07       Impact factor: 4.241

6.  Heart-type fatty acid binding protein and high-sensitivity troponin T are myocardial damage markers that could predict adverse clinical outcomes in patients with peripheral artery disease.

Authors:  Yoichiro Otaki; Hiroki Takahashi; Tetsu Watanabe; Gensai Yamaura; Akira Funayama; Takanori Arimoto; Tetsuro Shishido; Takuya Miyamoto; Isao Kubota
Journal:  BBA Clin       Date:  2015-06-18

7.  Clinical Significance of Skin Autofluorescence in Patients With Type 2 Diabetes Mellitus With Chronic Heart Failure.

Authors:  Takashi Hitsumoto
Journal:  Cardiol Res       Date:  2018-04-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.